Sildenafil for pulmonary hypertension: Dose-dependent improvement in exercise performance

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 3, 2008, Pages 516-521

  Spring, Riina Marjaana ^a   Ulrich, Silvia ^a   Huber, Lars C ^a   Speich, Rudolf ^a   Maggiorini, Marco ^a   Treder, Ursula ^a   Fischler, Manuel ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

6 min walking distance; Health related quality of life; Phosphodiesterase inhibitor; Pulmonary arterial hypertension (PAH); Pulmonary hypertension (PH); Sildenafil; Treatment

Indexed keywords

BOSENTAN; SILDENAFIL;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; EXERCISE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT RESPONSE; WALKING;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE; FEMALE; HEART RATE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; QUALITY OF LIFE; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING;

EID: 43049124136     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.11.006     Document Type: Article

References (35)

1. Galie N., Seeger W., Naeije R., Simonneau G., and Rubin L.J. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 81S-88S
2. Lee A.J., Chiao T.B., and Tsang M.P. Sildenafil for pulmonary hypertension. Ann Pharmacother 39 (2005) 869-884
3. Bharani A., Mathew V., Sahu A., and Lunia B. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 55 (2003) 55-59
4. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
5. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 40S-47S
6. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (2004) 5S-12S
7. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., and Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26 (2005) 858-863
8. A. T. S. Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
9. Borg G.A.V. Psycho-physical bases of perceived exertion. Med Sci Sports Exerc 14 (1982) 377-381
10. Cenedese E., Speich R., Dorschner L., Ulrich S., Maggiorini M., Jenni R., et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 28 (2006) 808-815
11. Raja S.G., and Nayak S.H. Sildenafil: emerging cardiovascular indications. Ann Thorac Surg 78 (2004) 1496-1506
12. Corbin J.D., and Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56 (2002) 453-459
13. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8 (1996) 47-52
14. Walker D.K., Ackland M.J., James G.C., Muirhead G.J., Rance D.J., Wastall P., et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29 (1999) 297-310
15. Gillies H.C., Roblin D., and Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 86 (2002) 131-141
16. Stief C.G., Uckert S., Becker A.J., Truss M.C., and Jonas U. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol 159 (1998) 1390-1393
17. Medina P., Segarra G., Vila J.M., Domenech C., Martinez-Leon J.B., and Lluch S. Effects of sildenafil on human penile blood vessels. Urology 56 (2000) 539-543
18. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., and Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction sildenafil study group. N Engl J Med 338 (1998) 1397-1404
19. Meuleman E., Cuzin B., Opsomer R.J., Hartmann U., Bailey M.J., Maytom M.C., et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 87 (2001) 75-81
20. Weimann J., Ullrich R., Hromi J., Fujino Y., Clark M.W., Bloch K.D., et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92 (2000) 1702-1712
21. Alaeddini J., Uber P.A., Park M.H., Scott R.L., Ventura H.O., and Mehra M.R. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 94 (2004) 1475-1477
22. Mikhail G.W., Prasad S.K., Li W., Rogers P., Chester A.H., Bayne S., et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 25 (2004) 431-436
23. Ghofrani H.A., Wiedemann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
24. Corris P., Burgess G., Parpia T., and Barst R. Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH). Eur Respir J 26 (2005) 475S
25. Hoeper M.M., and Welte T. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 354 (2006) 1091
26. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105 (2002) 2398-2403
27. Ulrich S., Fischler M., Speich R., Popov V., and Maggiorini M. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 130 (2006) 841-846
28. Sheth A., Park J.E., Ong Y.E., Ho T.B., and Madden B.P. Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascul Pharmacol 42 (2005) 41-45
29. Ghofrani H.A., Schermuly R.T., Rose F., Wiedemann R., Kohstall M.G., Kreckel A., et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167 (2003) 1139-1141
30. Alp S., Skrygan M., Schmidt W., and Bastian A. Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm Pharmacol Ther (2005) November 12; [Epub ahead of print]
31. Ghofrani H.A., Wiedemann R., Rose F., Schermuly R.T., Olschewski H., Weissmann N., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
32. Madden B., Allenby M., Loke T., and Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 44 (2006) 372-376
33. Humbert M., Sitbon O., and Simonneau G. Novel therapeutic perspectives in pulmonary arterial hypertension. Eur Respir J 22 (2003) 193-194
34. Hoeper M.M., Faulenbach C., Golpon H., Winkler J., Welte T., and Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24 (2004) 1007-1010
35. Paul G.A., Gibbs J.S., Boobis A.R., Abbas A., and Wilkins M.R. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 60 (2005) 107-112